Heart V5 predicts cardiac events in unresectable lung cancer patients undergoing chemoradiation.
Cardiac toxicity
chemoradiation
unresectable lung cancer
Journal
Journal of thoracic disease
ISSN: 2072-1439
Titre abrégé: J Thorac Dis
Pays: China
ID NLM: 101533916
Informations de publication
Date de publication:
Jun 2019
Jun 2019
Historique:
entrez:
3
8
2019
pubmed:
3
8
2019
medline:
3
8
2019
Statut:
ppublish
Résumé
Recent studies incorporating dose escalated radiation identified heart dose as a predictor of cardiac toxicity in unresectable lung cancer patients. Whether conventionally dosed radiation impacts cardiac events remains unclear. Stage III lung cancer patients undergoing definitive chemoradiation to 60-70 Gy were analyzed. Clinical and dosimetric factors (mean heart dose, heart V5-60 in 5 Gy increments) were analyzed against freedom from ≥ grade 3 cardiac events and overall survival (OS) by log-rank test. Multivariable analysis (MVA) for factors significant on univariate analysis was performed by Cox proportional hazards. A total of 108 patients were identified. Median follow-up was 18.0 months. One- and two-year OS were 79% and 61%, respectively. On MVA, gross tumor volume (GTV) ≥98.6 cm Heart V5 ≥49% predicted for cardiac events after chemoradiation. However, cardiac dosimetry was not associated with survival. Rather, female gender and GTV ≥98.6 cm
Sections du résumé
BACKGROUND
BACKGROUND
Recent studies incorporating dose escalated radiation identified heart dose as a predictor of cardiac toxicity in unresectable lung cancer patients. Whether conventionally dosed radiation impacts cardiac events remains unclear.
METHODS
METHODS
Stage III lung cancer patients undergoing definitive chemoradiation to 60-70 Gy were analyzed. Clinical and dosimetric factors (mean heart dose, heart V5-60 in 5 Gy increments) were analyzed against freedom from ≥ grade 3 cardiac events and overall survival (OS) by log-rank test. Multivariable analysis (MVA) for factors significant on univariate analysis was performed by Cox proportional hazards.
RESULTS
RESULTS
A total of 108 patients were identified. Median follow-up was 18.0 months. One- and two-year OS were 79% and 61%, respectively. On MVA, gross tumor volume (GTV) ≥98.6 cm
CONCLUSIONS
CONCLUSIONS
Heart V5 ≥49% predicted for cardiac events after chemoradiation. However, cardiac dosimetry was not associated with survival. Rather, female gender and GTV ≥98.6 cm
Identifiants
pubmed: 31372260
doi: 10.21037/jtd.2019.06.29
pii: jtd-11-06-2229
pmc: PMC6626817
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2229-2239Déclaration de conflit d'intérêts
Conflicts of Interest: The authors have no conflicts of interest to declare.
Références
Int J Radiat Oncol Biol Phys. 2001 Mar 1;49(3):649-55
pubmed: 11172945
Int J Radiat Oncol Biol Phys. 2002 Jan 1;52(1):49-57
pubmed: 11777621
Int J Radiat Oncol Biol Phys. 2002 Nov 1;54(3):735-41
pubmed: 12377325
JAMA. 2003 Dec 3;290(21):2831-7
pubmed: 14657067
Radiother Oncol. 2012 Jul;104(1):72-7
pubmed: 22682539
Cancer Res. 1990 Apr 1;50(7):2027-30
pubmed: 2317792
N Engl J Med. 2013 Mar 14;368(11):987-98
pubmed: 23484825
Radiother Oncol. 2015 Jan;114(1):85-90
pubmed: 25554226
Lancet Oncol. 2015 Feb;16(2):187-99
pubmed: 25601342
Front Oncol. 2015 Feb 18;5:39
pubmed: 25741474
Int J Radiat Oncol Biol Phys. 2016 Mar 1;94(3):612-20
pubmed: 26867890
Radiother Oncol. 2016 Jun;119(3):495-500
pubmed: 27189523
Oncol Lett. 2016 Aug;12(2):1144-1148
pubmed: 27446409
Lancet Oncol. 2016 Sep;17(9):1325-34
pubmed: 27470081
J Thorac Oncol. 2017 Feb;12(2):293-301
pubmed: 27743888
J Clin Oncol. 2017 Jan;35(1):56-62
pubmed: 28034064
J Clin Oncol. 2017 Apr 10;35(11):1171-1178
pubmed: 28095159
J Clin Oncol. 2017 May 1;35(13):1387-1394
pubmed: 28113017
Blood. 2017 Apr 20;129(16):2257-2265
pubmed: 28143884
J Clin Oncol. 2017 May 1;35(13):1395-1402
pubmed: 28301264
Ann Oncol. 2017 May 1;28(5):1084-1089
pubmed: 28453703
Lancet Oncol. 2017 Aug;18(8):1116-1125
pubmed: 28642008
Int J Radiat Oncol Biol Phys. 2017 Aug 1;98(5):1116-1123
pubmed: 28721895
Int J Radiat Oncol Biol Phys. 2017 Sep 1;99(1):70-79
pubmed: 28816165
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
N Engl J Med. 1995 Jun 29;332(26):1738-43
pubmed: 7760889
Med Pediatr Oncol. 1993;21(7):477-9
pubmed: 8341214
N Engl J Med. 1999 Jan 28;340(4):265-71
pubmed: 9920950